Brivaracetam and seletracetam, two new SV2A ligands, improve paroxysmal dystonia in the dtsz mutant hamster

European Journal of Pharmacology

Volumn 601, Issue 1-3, 2008, Pages 99-102

  Hamann, Melanie ^a   Sander, Svenja E ^a   Richter, Angelika ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

Antiepileptic drug; Dyskinesia; Dystonic choreoathetosis; Movement disorder; SV2A ligand; Therapeutic

Indexed keywords

BRIVARACETAM; ETIRACETAM; LIGAND; MEMBRANE PROTEIN; PYRROLIDINE DERIVATIVE; SELETRACETAM; SYNAPTIC VESICLE PROTEIN 2A; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG POTENCY; DT SZ HAMSTER; DYSKINESIA; GENE MUTATION; MEMBRANE VESICLE; NONHUMAN; PAROXYSMAL DYSTONIA; PRIORITY JOURNAL; SYRIAN HAMSTER;

ANIMALS; CRICETINAE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DYSTONIA; HUMANS; LIGANDS; MEMBRANE GLYCOPROTEINS; NERVE TISSUE PROTEINS; PIRACETAM; PYRROLIDINONES; SEVERITY OF ILLNESS INDEX;

EID: 56949101467     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2008.10.048     Document Type: Article

References (32)

1. Breakefield X.O., Blood A.J., Li Y., Hallett M., Hanson P.I., and Standaert D.G. The pathophysiological basis of dystonias. Nat. Rev. Neurosci. 9 (2008) 222-234
2. Chatterjee A., Louis E.D., and Frucht S. Levetiracetam in the treatment of paroxysmal kinesiogenic choreoathetosis. Mov. Disord. 17 (2002) 614-615
3. de Tommaso M., Di Fruscolo O., Sciruicchio V., Specchio N., Cormio C., De Caro M.F., and Livrea P. Efficacy of levetiracetam in Huntington disease. Clin. Neuropharmacol. 28 (2005) 280-284
4. Fahn S., Bressman S.B., and Marsden C.D. Classification of dystonia. Adv. Neurol. 78 (1998) 1-10
5. Fuks B., Gillard M., Michel P., Lynch B., Vertongen P., Leprince P., Klitgaard H., and Chatelain P. Localization and photoaffinity labelling of the levetiracetam binding site in rat brain and certain cell lines. Eur. J. Pharmacol. 478 (2003) 11-19
6. A receptor agonists and antagonists in a genetic animal model of paroxysmal dystonia. Eur. J. Pharmacol. 443 (2002) 59-70
7. Hering S., Wenning G.K., Seppi K., Poewe W., and Mueller J. An open trial of levetiracetam for segmental and generalized dystonia. Mov. Disord. 22 (2007) 1649-1651
8. Hill M.P., Bezard E., McGuire S.G., Crossman A.R., Brotchie J.M., Michel A., Grimee R., and Klitgaard H. Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L-dopa and ropinirole in the MPTP-lesioned marmoset. Mov. Disord. 18 (2003) 1301-1305
9. Jankovic J. Treatment of dystonia. Lancet Neurol. 5 (2006) 864-872
10. Klitgaard H., Matagne A., Gobert J., and Wulfert E. Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. Eur. J. Pharmacol. 353 (1998) 191-206
11. Löscher W., and Richter A. Piracetam and levetiracetam, two pyrrolidone derivatives, exert antidystonic effects in a hamster model of paroxysmal dystonia. Eur. J. Pharmacol. 391 (2000) 251-254
12. Lynch B.A., Lambeng N., Nocka K., Kensel-Hammes P., Bajjalieh S.M., Matagne A., and Fuks B. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc. Natl. Acad. Sci. USA. 101 (2004) 9861-9866
13. Madeja M., Margineanu D.G., Gorji A., Siep E., Boerrigter P., Klitgaard H., and Speckmann E.-J. Reduction of voltage-operated potassium currents by levetiracetam: a novel antiepileptic mechanism of action?. Neuropharmacology 45 (2003) 661-671
14. McGavin C.L., John V., and Musser W.S. Levetiracetam as a treatment for tardive dyskinesia: a case report. Neurology 61 (2003) 419
15. Mink J.W. The basal ganglia and involuntary movements: impaired inhibition of competing motor patterns. Arch. Neurol. 60 (2003) 1365-1368
16. Niespodziany I., Klitgaard H., and Margineanu D.G. Is the persistent sodium current a specific target of anti-absence drugs?. NeuroReport 15 (2004) 1049-1052
17. Noyer M., Gillard M., Matagne A., Hénichart J.P., and Wülfert E. The novel antiepileptic drug levetiracetam (ucb L059) appears to act via a specific binding site in CNS membranes. Eur. J. Pharmacol. 286 (1995) 137-146
18. Pisani A., Bonsi P., Martella G., De Persis C., Costa C., Pisani F., Bernardi G., and Calabresi P. Intracellular calcium increase in epileptiform activity: modulation by levetiracetam and lamotrigine. Epilepsia 45 (2004) 719-728
19. Richter A. The genetically dystonic hamster: an animal model of paroxysmal dystonia. In: LeDoux M. (Ed). Animal Models of Movement Disorders (2005), Elsevier Academic Press, San Diego 459-466
20. Richter A., and Löscher W. Pathophysiology of idiopathic dystonia: findings from genetic animal models. Prog. Neurobiol. 54 (1998) 633-677
21. Richter A., and Löscher W. Animal models of paroxysmal dyskinesia. Adv. Neurol. 89 (2002) 443-451
22. 2+ channel antagonists in a hamster model of idiopathic dystonia. Eur. J. Pharmacol. 300 (1996) 197-202
23. sz mutant, an animal model of hereditary paroxysmal dystonia. Br. J. Pharmacol. 149 (2006) 747-753
24. Rigo J.M., Hans G., Nguyen L., Rocher V., Belachew S., Malgrange B., Leprince P., Moonen G., Selak I., Matagne A., and Klitgaard H. The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA- and glycine-gated currents. Br. J. Pharmacol. 136 (2002) 659-672
25. Rogawski M.A. Diverse mechanisms of antiepileptic drugs in the development pipeline. Epilepsy Res. 69 (2006) 273-294
26. Rogawski M.A., and Löscher W. The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions. Nat. Med. 10 (2004) 685-692
27. Saunders-Pullman R., and Bressman S. Clinical features and classification of the human dystonias. In: LeDoux M. (Ed). Animal Models of Movement Disorders (2005), Elsevier Academic Press, San Diego 227-240
28. Stefan H., and Feuerstein T.J. Novel anticonvulsant drugs. Pharmacol. Ther. 113 (2007) 165-183
29. Sullivan K.L., Hauser R.A., Louis E.D., Chari G., and Zesiewicz T.A. Levetiracetam for the treatment of generalized dystonia. Parkinsonism Relat. Disord. 11 (2005) 469-471
30. Tarsy D., Ryan R.K., and Ro S.I. An open-label trial of levetiracetam for treatment of cervical dystonia. Mov. Disord. 21 (2006) 734-735
31. Yardimci N., Karatas M., Kilinc M., and Benli S. Levetiracetam in Meige's syndrome. Acta Neurol. Scand. 114 (2006) 63-66
32. Zesiewicz T.A., Sullivan K.L., Maldonado J.L., Tatum W.O., and Hauser R.A. Open-label pilot study of levetiracetam (Keppra) for the treatment of levodopa-induced dyskinesias in Parkinson's disease. Mov. Disord. 20 (2005) 1205-1209